Table 1.
Standard-dose CT with FBP | Low-dose CT with FBP | Low-dose CT with ASIR | Low-dose CT with MBIR | |
---|---|---|---|---|
Consolidation or mass |
4.9 ± 0.2 |
4.7 ± 0.6 |
4.8 ± 0.4 |
4.9 ± 0.2 |
Ground-glass attenuation |
5.0 ± 0.2 |
4.8 ± 0.4 |
4.8 ± 0.4 |
4.8 ± 0.4 |
Reticular opacity |
5.0 ± 0 |
4.9 ± 0.4 |
5.0 ± 0 |
5.0 ± 0 |
Decreased lung attenuation (bulla, emphysema, or cyst) |
4.9 ± 0.2 |
4.5 ± 0.6 *§ |
4.6 ± 0.5 *§ |
4.9 ± 0.2 |
Mediastinal lymph node enlargement | 4.8 ± 0.4 | 3.0 ± 0.5 *§ | 4.0 ± 0.5 *§ | 4.7 ± 0.5 |
CT Computed tomography, FBP Filtered back projection, ASIR Adaptive statistical iterative reconstruction, MBIR Model-based iterative reconstruction.
The comparisons of lesion conspicuity scores were made by the Wilcoxon signed-rank test. * refers to statistically significant differences with standard-dose FBP CT (* p < 0.05). § refers to statistically significant differences with low-dose MBIR CT (§ p < 0.05).